Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Abstract

Inhibition of hepatic drug metabolism in VX2 carcinoma-bearing rabbits.

M Weiner and J W Olson
Drug Metabolism and Disposition May 1980, 8 (3) 139-142; DOI: https://doi.org/10.1124/dmd.8.3.139
M Weiner
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J W Olson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Hepatic metabolism of aniline, p-chloro-N-methylaniline, and aminopyrine was determined in control male, New Zealand White rabbits or those bearing VX2 carcinoma (a prostaglandin-secreting tumor). In addition, the levels of cyclic AMP and cyclic GMP in the liver and the concentration of calcium in serum were examined. After 13 days of tumor growth, metabolism of aminopyrine and PCMA was decreased by approximately 30%, whereas aniline metabolism was not significantly altered. Metabolism of all substrates was significantly depressed to 20-60% of control by 22 days after transplantation. Serum calcium levels increased by 14 and 29% after 13 and 22 days, respectively. The ratio of cyclic AMP to cyclic GMP was 156% of control after 13 days and 139% by 22 days of tumor growth. The increased ratio was due solely to a change in cyclic AMP concentration. A 20-min pretreatment with prostaglandin E1, 0.3 mg/kg ip, depressed in vitro hepatic metabolism of all substrates by 27-56% while increasing cyclic AMP levels by 42%.

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition
Vol. 8, Issue 3
1 May 1980
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Inhibition of hepatic drug metabolism in VX2 carcinoma-bearing rabbits.
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Abstract

Inhibition of hepatic drug metabolism in VX2 carcinoma-bearing rabbits.

M Weiner and J W Olson
Drug Metabolism and Disposition May 1, 1980, 8 (3) 139-142; DOI: https://doi.org/10.1124/dmd.8.3.139

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Abstract

Inhibition of hepatic drug metabolism in VX2 carcinoma-bearing rabbits.

M Weiner and J W Olson
Drug Metabolism and Disposition May 1, 1980, 8 (3) 139-142; DOI: https://doi.org/10.1124/dmd.8.3.139
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics